BNTXBioNTech SERunning, no new patients
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Unresectable Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Cancer · Recurrent Head and Neck Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 358 (final count)
- Started
- Jan 7, 2021
- Main results expected
- Apr 2029
- Fully finished
- Apr 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part A - Occurrence of treatment-emergent adverse event (TEAE) - BNT113 in combination with pembrolizumab
Measured over: up to 27 months
Part B - Overall survival (OS)
Measured over: up to 48 months
Part B - Progression-free survival (PFS)
Measured over: up to 48 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04534205 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC